All News

A new research study, published in JAMA Cardiology, aimed to further confirm a previous correlation between asthma and atrial fibrillation (AF) and to determine if the degree of asthma control affected the risk of developing AF.

The FDA on Friday approved Pfizer's filgrastim-aafi, a filgrastim biosimilar to Amgen's Neupogen.

Data collected from a number of patient safety reporting programs indicate that between 2% and 35% of prescription errors are linked to look alike, sound alike drug name similarities.

There is a concern that mergers and acquisitions in the pharmacy space will lead to decreased competition and loose agreements between companies that will not drive significant outcomes.

Study suggests benzalkonium chloride, a preservative that has been used in ophthalmology since the 1940s, may be toxic to ocular structures.

Stay tuned all week to watch our Editor in Chief's RAGBRAI ride with the Iowa Pharmacy Association.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

The HIV pandemic will likely continue to be a global challenge for the foreseeable future.

Mapping iron concentration in certain regions of the brain may help predict multiple sclerosis progression risk.

Approval for tafenoquine was granted based on the efficacy and safety data gleaned from a comprehensive global clinical development program for P vivax prevention of relapse,

He is recognized in the field of social and administrative pharmacy by the American Association of College of Pharmacy at its annual meeting in Boston, Massachusetts.

All week, Pharmacy Times Editor in Chief Troy Trygstad will be providing updates on this website about his ride across Iowa with the IPA.

All week, Pharmacy Times Editor in Chief Troy Trygstad will be providing updates on this website about his ride across Iowa with the IPA.

The approval of ivosidenib fills an unmet need for patients with relapsed or refractory acute myeloid leukemia who have an IDH1 genetic mutation.

Survivors of cancer in adolescence and young adulthood may be at higher risk for endocrine diseases, such as thyroid disease, testicular dysfunction, and diabetes.

Gene-editing technology could lead to new targeted therapies and help clinicians catch developing cancers before they metastasize.

Genentech announced that the FDA has granted Breakthrough Therapy Designation to atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) as a first-line treatment for patients with the most common form of liver cancer.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Tallin's nearly 600 year old pharmacy Raeapteek offers an in depth view into the practice of pharmacy in Estonia.

The onus to have properly-trained pharmacists has shifted from the specialty pharmacy to the individual.

New research has associated certain health problems with later diagnosis of multiple sclerosis.

Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) is the first and only complete darunavir-based single tablet regimen (STR) for the treatment of HIV-1 in treatment-naïve and certain virologically suppressed adults.

The report compared the tolerability and safety of CGRP inhibitors—erenumab, fremanezumab, and galcanezumab—to no preventive treatment or commonly-used preventive therapies.

Based on 2017 FDA research, the delayed market launch of nine biosimilars represented $4.5 billion in potential savings.

Top news of the day from across the health care landscape.

The investigational treatment could benefit patients with amyotrophic lateral sclerosis whose disease is caused by mutations in the SOD1 gene.